ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER S DISEASE IN THE NEW ENGLAND streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.
STOCKHOLM, Nov. 30, 2022 /PRNewswire/ BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory